A recent study published in Genes & Diseases by researchers from Jiangsu University, Wuxi Ninth People's Hospital Affiliated to Soochow University, Shenzhen International Institute for Biomedical Research, Shenzhen Walgenron Bio-Pharm Co., Ltd., The Affiliated Suzhou Hospital of Nanjing Medical University, The University of Chicago Medical Center and The First Affiliated Hospital of Soochow University identifies microRNA-101a (miR-101a) as a critical suppressor of chondrocyte hypertrophy and a potential therapeutic candidate for OA intervention.

Initial in silico analyses using four prediction platforms (TargetScan, PicTar, miRDB, and miRCODE) highlighted miR-101a as one of the few miRNAs capable of targeting both Cox-2 and Col10a1. Experimental validation in MCT and ATDC5 chondrocyte models showed that miR-101a expression markedly decreases during hypertrophic differentiation, while Cox-2 and Col10a1 levels rise significantly. Overexpression of miR-101a sharply reduced their expression—and also diminished MMP-13—whereas miR-101a inhibition produced the opposite effect. Importantly, luciferase reporter assays confirmed Cox-2 as a direct target of miR-101a, indicating that suppression of Col10a1 occurs secondarily through Cox-2 regulation.

To assess the translational potential of restoring miR-101a levels in vivo, the researchers administered miR-101a agomir via intra-articular injection in a destabilization of the medial meniscus (DMM)–induced OA mouse model. Treated mice exhibited reduced Col10a1 expression, preserved chondrocyte density, improved cartilage thickness, and significantly attenuated structural damage compared with control groups. These findings collectively establish miR-101a as a key epigenetic regulator of hypertrophy-driven cartilage degeneration.

These results highlight a crucial epigenetic mechanism controlling hypertrophic cartilage degeneration, with miR-101a functioning as a negative regulator of hypertrophy through its direct repression of Cox-2. The authors note that further studies—such as integrating micro-CT imaging and evaluating positive drug controls—will strengthen the translational potential of miR-101a–based therapies.

In conclusion, targeting miR-101a offers a promising strategy for next-generation OA therapies by directly inhibiting Cox-2-mediated hypertrophy while reducing downstream cartilage degradation. As OA continues to impose a growing global health burden, miRNA-based interventions such as miR-101a restoration may represent a transformative direction for future disease-modifying treatments.

Funding Information:
The Jiangsu Provincial Key Research and Development Program (China) (No. BE2020679)
The Innovation Team (leader) of Jiangsu Province, China (2017)
Science Foundation of Jiangsu Province (China) (No. BK20240371)
The National Science Foundation of China (No. 81901632; No.82001576)
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus Cite Score: 8.4
Impact Factor: 9.4
# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases )

# # # # # #